EP4248990A3 - Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma - Google Patents

Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma Download PDF

Info

Publication number
EP4248990A3
EP4248990A3 EP23174335.2A EP23174335A EP4248990A3 EP 4248990 A3 EP4248990 A3 EP 4248990A3 EP 23174335 A EP23174335 A EP 23174335A EP 4248990 A3 EP4248990 A3 EP 4248990A3
Authority
EP
European Patent Office
Prior art keywords
lymphoma
nivolumab
blockade
refractory hodgkin
hodgkin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23174335.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4248990A2 (en
Inventor
Benedetto FARSACI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4248990(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP4248990A2 publication Critical patent/EP4248990A2/en
Publication of EP4248990A3 publication Critical patent/EP4248990A3/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP23174335.2A 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma Pending EP4248990A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344880P 2016-06-02 2016-06-02
PCT/US2017/035492 WO2017210453A1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
EP17730627.1A EP3463457B1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP17730627.1A Division EP3463457B1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
EP17730627.1A Division-Into EP3463457B1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Publications (2)

Publication Number Publication Date
EP4248990A2 EP4248990A2 (en) 2023-09-27
EP4248990A3 true EP4248990A3 (en) 2024-01-03

Family

ID=59067911

Family Applications (2)

Application Number Title Priority Date Filing Date
EP23174335.2A Pending EP4248990A3 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
EP17730627.1A Active EP3463457B1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP17730627.1A Active EP3463457B1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Country Status (17)

Country Link
US (3) US11083790B2 (enExample)
EP (2) EP4248990A3 (enExample)
JP (3) JP7175198B2 (enExample)
KR (2) KR20230038318A (enExample)
CN (1) CN109475633A (enExample)
DK (1) DK3463457T3 (enExample)
ES (1) ES2954139T3 (enExample)
FI (1) FI3463457T3 (enExample)
HR (1) HRP20230864T1 (enExample)
HU (1) HUE062398T2 (enExample)
LT (1) LT3463457T (enExample)
PL (1) PL3463457T3 (enExample)
PT (1) PT3463457T (enExample)
RS (1) RS64388B1 (enExample)
SI (1) SI3463457T1 (enExample)
SM (1) SMT202300290T1 (enExample)
WO (1) WO2017210453A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
FI3464368T3 (fi) 2016-06-02 2023-09-12 Bristol Myers Squibb Co Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa
CN109475633A (zh) 2016-06-02 2019-03-15 百时美施贵宝公司 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1
MX2020006171A (es) * 2018-01-12 2020-09-03 Bristol Myers Squibb Co Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
WO2020135415A1 (zh) * 2018-12-24 2020-07-02 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
WO2020198672A1 (en) * 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
WO2025136845A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Methods of treating a patient with a pd-1 antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20060032289A1 (en) 2004-08-11 2006-02-16 Pinnaduwage Lal A Non-optical explosive sensor based on two-track piezoresistive microcantilever
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
NO2504364T3 (enExample) 2009-11-24 2018-01-06
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2012122444A1 (en) 2011-03-10 2012-09-13 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
WO2014028560A2 (en) * 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN109475633A (zh) 2016-06-02 2019-03-15 百时美施贵宝公司 在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOSEPH MALY ET AL: "Pembrolizumab in classical Hodgkin's lymphoma", EUROPEAN JOURNAL OF HAEMATOLOGY, MUNSKGAARD, COPENHAGEN, DK, vol. 97, no. 3, 30 May 2016 (2016-05-30), pages 219 - 227, XP071760753, ISSN: 0902-4441, DOI: 10.1111/EJH.12770 *
MOSKOWITZ CRAIG H ET AL: "PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 124, no. 21, 14 November 2014 (2014-11-14), pages 290, XP086739156, ISSN: 0006-4971, [retrieved on 20210625], DOI: 10.1182/BLOOD.V124.21.290.290 *
STEPHEN M. ANSELL ET AL: "PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM -, vol. 372, no. 4, 22 January 2015 (2015-01-22), pages 311 - 319, XP055239003, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1411087 *

Also Published As

Publication number Publication date
RS64388B1 (sr) 2023-08-31
JP2025020119A (ja) 2025-02-12
SI3463457T1 (sl) 2023-09-29
EP4248990A2 (en) 2023-09-27
LT3463457T (lt) 2023-09-11
FI3463457T3 (fi) 2023-09-12
KR20230038318A (ko) 2023-03-17
WO2017210453A1 (en) 2017-12-07
KR20190015377A (ko) 2019-02-13
EP3463457A1 (en) 2019-04-10
JP2019517504A (ja) 2019-06-24
ES2954139T3 (es) 2023-11-20
JP7568698B2 (ja) 2024-10-16
PL3463457T3 (pl) 2023-08-21
DK3463457T3 (da) 2023-10-02
HRP20230864T1 (hr) 2023-11-10
HUE062398T2 (hu) 2023-10-28
US20250134996A1 (en) 2025-05-01
SMT202300290T1 (it) 2023-11-13
US11083790B2 (en) 2021-08-10
JP2023025012A (ja) 2023-02-21
US20220025049A1 (en) 2022-01-27
CN109475633A (zh) 2019-03-15
EP3463457B1 (en) 2023-06-28
JP7175198B2 (ja) 2022-11-18
PT3463457T (pt) 2023-09-07
US20190290757A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
NZ739750A (en) Anti-tigit antibodies and methods of use
MX2020006668A (es) Anticuerpos para lilrb2.
PH12016501411A1 (en) Bifunctional cytotoxic agents
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX378457B (es) Anticuerpos siglec de reacciòn cruzada.
MX2022003571A (es) Uso de un anticuerpo anti-pd-1 en combinacion con un anticuerpo anti- cd30 para el tratamiento de linfoma.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EP4631978A3 (en) Humanized or chimeric cd3 antibodies
NZ746755A (en) Anti-tim-3 antibodies and compositions
WO2016004389A3 (en) Monovalent binding proteins
TW201713698A (en) PD-1 antibodies
EP3872094A3 (en) Antibodies targeting b-cell maturation antigen and methods of use
EP4548927A3 (en) Methods and compositions for chimeric antigen receptor targeting cancer cells
EP4124624A3 (en) Antibodies against canine pd-1
MX2022001105A (es) Anticuerpos anti tigit.
MA39909A (fr) Conjugué anticorps de l&#39;igf-1r-médicament et son utilisation pour le traitement du cancer
EP4512827A3 (en) Compositions and methods for treating autoimmune diseases and cancers
JO3567B1 (ar) جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP4269421A3 (en) Tem8 antibodies and their use
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer&#39;s disease
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
EP3988673A3 (en) Variants of tnfsf15 and dcr3 associated with crohn&#39;s disease
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
WO2015179469A3 (en) Methods and compositions for treating malignancies with dendritic cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3463457

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039000000

Ipc: A61K0039395000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALN20231128BHEP

Ipc: C07K 16/28 20060101ALI20231128BHEP

Ipc: A61K 39/395 20060101AFI20231128BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40098571

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240701

RAX Requested extension states of the european patent have changed

Extension state: ME

Payment date: 20240701

Extension state: BA

Payment date: 20240701

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR